The brief negative symptom scale: psychometric properties.
Brian Kirkpatrick, Gregory P Strauss, Linh Nguyen...
https://pubmed.ncbi.nlm.nih.gov/20558531/Actively Recruiting
Led by Lithuanian University of Health Sciences · Updated on 2024-02-26
200
Participants Needed
2
Research Sites
N/A
Total Duration
This research aims to validate the Lithuanian versions of three diagnostic tools the Brief Negative Symptoms Scale, the Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale. These tools assess negative symptoms, depressive symptoms, and cognitive deficits in people with schizophrenia. The study compares these results with established scales including the Positive and Negative Symptoms Scale, Montgomery Asberg Depression Rating Scale, and Montreal Cognitive Assessment to ensure accuracy and relevance in a Lithuanian sample. The study involves using the Lithuanian versions of these three scales, which are semi-structured interviews with multiple items assessing specific symptoms of schizophrenia. The Brief Negative Symptoms Scale focuses on negative symptoms, the Calgary Depression Scale evaluates depressive symptoms in schizophrenia patients, and the Schizophrenia Cognition Rating Scale assesses cognitive deficits. Participants will be evaluated using these scales alongside other established assessments for comparison. Participants will undergo evaluations using several symptom and cognition assessment tools during a single study visit Day 1. Researchers will analyze correlations between negative symptoms, depressive symptoms, cognitive deficits, and health-related quality of life. The primary outcome is the validation of the Lithuanian versions of the three scales. The study is observational, with no treatment intervention, and participants are involved in diagnostic interviews and standard assessments during their participation.
CONDITIONS
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
J
Jonas Montvidas, MD
A
Algirdas Musneckis, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Lithuanian University of Health Sciences
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants complete assessments using the Lithuanian versions of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale to validate these tools and evaluate symptoms.
1 visit (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Brian Kirkpatrick, Gregory P Strauss, Linh Nguyen...
https://pubmed.ncbi.nlm.nih.gov/20558531/Matthias J Müller, Helena Brening, Christoph Gensch...
https://pubmed.ncbi.nlm.nih.gov/16040126/Richard S E Keefe, Vicki G Davis, Nathan B Spagnola...
https://pubmed.ncbi.nlm.nih.gov/25028065/Lithuanian University of Health Sciences
Lead Sponsor